| Date | Target |
Transaction Type Value: $mlns |
Acquirer | Seller | ||
|---|---|---|---|---|---|---|
| 2013-12-18 |
Respira
Life Science Palo Alto, California www.respiratherapeutics.com Respira is a pharmaceutical development company focused on commercializing its high-efficiency, dry powder inhaler (DPI) drug delivery technologies for the treatment of important diseases with unmet clinical needs. Respira was founded in 2010 and is based in Palo Alto, California. |
Venture |
Sun Mountain Capital
|
- | ||
| 2013-12-12 |
Senhwa Biosciences
Life Science New Taipei City, Taiwan www.senhwabio.com Senhwa Biosciences is a drug development company, that engages in the development of new drugs and special pharmaceutical ingredients. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors and BRCA2 and/or PALB2 mutation. Senhwa Biosciences was founded in 2012 and is based in New Taipei City, Taiwan. |
Venture |
H&Q Asia Pacific
|
- | ||
| Deal Article Deal Link | ||||||
| 2013-10-30 |
Dimension Therapeutics
Life Science Cambridge, Massachusetts www.dimensiontx.com Dimension Therapeutics is a developer of new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts. |
Venture |
Eight Roads
|
- | ||
| 2013-10-04 |
PharmAkea
Life Science San Diego, California www.pharmakea.com PharmAkea is a biopharmaceutical company and is a developer of high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases. PharmAkea was founded in 2012 and is based in San Diego, California. |
Venture |
Bay City Capital
Celgene Corp.
|
- | ||
| 2013-10-01 |
Cydan
Life Science Cambridge, Massachusetts www.cydanco.com Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative, and capital efficient manner. Cydan was founded in 2013 and is based in Cambridge, Massachusetts. |
Venture |
Bay City Capital
|
- | ||
| 2013-09-18 |
Vivex
Life Science Miami, Florida www.vivex.com Vivex specialized in the development of naturally sourced treatment options and solutions that improve clinical, surgical, and therapeutic patient care through innovation. Vivex Biomedical is based in Miami, Florida. |
Venture |
JAM Capital Partners
|
- | ||
| 2013-09-12 |
Covagen AG
Life Science Zurich, Switzerland www.covagen.com Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. |
Venture |
GIMV
|
- | ||
| 2013-07-10 |
Loxo Oncology, Inc.
Life Science Stamford, Connecticut www.loxooncology.com Loxo Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is based in Stamford, Connecticut. |
Venture |
Aisling Capital
|
- | ||
| 2013-07-09 |
OncoEthix SA
Life Science Lausanne, Switzerland OncoEthix is a privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an investigational orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase I clinical studies in healthy volunteers. |
Venture |
Edmond de Rothschild Private Equity
|
- | ||
| 2013-06-26 |
Complix
Life Science Ghent, Belgium www.complix.com Complix is focused on the discovery and development of alpha bodies, a novel class of biopharmaceuticals that, due to their unique structural and functional properties, are particularly suited to address disease targets that are difficult to reach with antibodies or other types of therapeutic protein scaffolds. Complix was founded in 2008 and is based in Ghent, Belguim. |
Venture |
GIMV
Andera Partners
|
- | ||
| 2013-06-26 |
Kiadis Pharma
Life Science Amsterdam, Netherlands www.kiadis.com Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands. |
Venture |
Alta Partners
EQT Life Sciences
|
- | ||
| 2013-06-26 |
Rapid Micro Biosystems
Life Science Lowell, Massachusetts www.rapidmicrobio.com Rapid Micro Biosystems is a life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Rapid Micro Biosystems was founded in 2006 and is based in Lowell, Massachusetts. |
Venture |
TPG
|
- | ||
| Deal Article Deal Link | ||||||
| 2013-05-12 |
Eurocept
Life Science Houten, Netherlands www.eurocept.nl Eurocept is a healthcare company offering a unique combination of specialty pharma and medical homecare. Eurocept Pharmaceuticals is responsible for the registration, marketing, distribution and sale of speciality medicines in the fields of anesthetics, psychiatry, urology, pediatrics and infectious diseases. Eurocept Homecare provides medical specialist homecare and related out-patient medical technology for medicine and food administration. Eurocept was founded in 2001 and is based in Houten, Netherlands. |
Venture |
GIMV
|
- | ||
| Deal Article Deal Link | ||||||
| 2013-05-08 |
Lumena Pharmaceuticals, Inc.
Life Science San Diego, California www.lumenapharma.com Lumena Pharmaceuticals is a privately-held biotechnology company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. |
Venture |
Alta Partners
|
- | ||
| 2013-05-08 |
Antidote
Life Science North Miami Beach, Florida www.antidote.me Antidote is a digital health company that connects patients with clinical research through its online trial-matching platform. The Company partners with pharmaceutical sponsors, CROs, and advocacy groups to accelerate clinical trial recruitment using data-driven tools and patient engagement campaigns. Antidote was founded in 2010 and is based in North Miami Beach, Florida. |
Venture |
Smedvig Capital
Octopus Investments
Amadeus Capital Partners
LBO France
|
- | ||
| 2013-04-15 |
Galleon Pharmaceuticals
Life Science Horsham, Pennsylvania Galleon Pharmaceuticals engages in the pharmaceutical treatment of sleep apnea and related breathing-control disorders. Galleon Pharmaceuticals was founded in 2003 and is based in Horsham, Pennsylvania. |
Venture |
TPG
MPE Partners
|
- | ||
| Deal Article Deal Link | ||||||
| Avg |
$0.0
0.0x EBITDA 0.0x REVENUE |
|||||
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr was built to simplify the process of tracking who’s buying, selling, and what deals are happening across the private markets.
Behind every transaction is an opportunity, and Mergr gives professionals access to thousands of M&A deals, along with the investors, buyers, and sellers behind them.
The platform is powerful but easy to use — so you can quickly surface relevant transactions and move from research to action.
Full access to Mergr's investor, acquirer, and transaction data starts here.
